Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial

American Journal of Hematology

Volumn 90, Issue 7, 2015, Pages 634-638

  Calvaruso, Giuseppina ^a   Vitrano, Angela ^a   Di Maggio, Rosario ^a   Lai, Eliana ^b   Colletta, Grazia ^c   Quota, Alessandra ^d   Gerardi, Calogera ^e   Rigoli, Luciana Concetta ^f   Sacco, Massimiliano ^a   Pitrolo, Lorella ^a   Maggio, Aurelio ^a  

^a Sofia Cervello   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d Centro Microcitemia   (Italy)

^e UOS Di Talassemia   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADULT; AGRANULOCYTOSIS; ARTHRALGIA; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IRON CHELATION; LEUKOCYTE COUNT; LONG TERM CARE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THALASSEMIA INTERMEDIA; THROMBOCYTE COUNT; TREATMENT DURATION; ADVERSE EFFECTS; BETA-THALASSEMIA; CHELATION THERAPY; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; IRON OVERLOAD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; STATISTICAL MODEL; SURVIVAL;

ADULT; AGRANULOCYTOSIS; ARTHRALGIA; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; DEFEROXAMINE; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LINEAR MODELS; MALE; MIDDLE AGED; NEUTROPENIA; PYRIDONES; SURVIVAL ANALYSIS;

EID: 84931956904     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24024     Document Type: Article

References (20)

1. Olivieri NF. The β-thalassemias. N Engl J Med 1999;341:99-109.
2. Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalas- semia intermedia. Haematologica 2011;96:1605-1612.
3. Viprakasit V, Lee-Lee C, Chong QT, et al. Iron chelation therapy in the management of thalassemia: The Asian perspectives. Int J Hematol 2009;90:435-445.
4. Olivieri N. Adherence to deferoxamine therapy: Heeding hippocrates and osler. Am J Hematol 2004;76:415-416.
5. Taher AT, Porter JB, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-Year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012;120:970-977
6. Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-Year extension results from the THALASSA study. Ann Hematol 2013;92:1485-1493.
7. Maggio A, D'Amico G, Morabito A. Independent clinical trials. Lancet 2004;363:1080.
8. Maggio A1, Giambona A, Cai SP, et al. Rapid and simultaneous typing of hemoglobin S, hemoglobin C, and seven Mediterranean beta-thalassemia mutations by covalent reverse dot-blot analysis: Application to prenatal diagnosis in Sicily. Blood 1993;81:239-242.
9. Rochon J. Sample size calculations for two-group repeated measures experiments. Biometrics 1991;47:1383-1398.
10. Faraway, Julian J. Extending the linear model with R: Generalized linear, mixed effects and nonparametric regression models. Boca Raton: Chapman Hall; 2006.
11. Collett, David. Modelling survival data in medical research. Boca Raton: Chapman Hall; 2003.
12. Akrawinthawong K, Chaowalit N, Chatuparisuth T, et al. Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. Hematology 2011;16:113-122.
13. Pootrakul P1, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003;122:305-310.
14. Rombos Y, Tzanetea R, Konstantopoulos K, et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 2000;85:115-117.
15. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalizationof serum ferritin during treatment with the oral iron chelator l1 in thalassemia intermedia. Blood 1992;79:2741-2748.
16. Chan JC, Chim CS, Ooi CG, et al. Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease. Br J Haematol 2006;133:198-205.
17. Musallam KM, Cappellini MD, Daar S, et al.Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: The ORIENT study. Haematologica, in press. pii: haematol.2013.097220. [Epub ahead of print]
18. Karam LB, Disco D, Jackson SM, et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions: Poor correlation with ferritin levels. Pediatr Blood Cancer 2008;50:62-65.
19. Taher A, Porter J, Viprakasit V, et al. Estimation of liver iron concentration by serum ferritin measurement in non-transfusion-depedent thalassemia patients: Analysis from the 1-year THALASSA study (abstract). Haematologica 2012;96:0927
20. Taher A, Porter J, Viprakasit V, et al. Serum ferritin for predicting clinically relevant LIC thresholds to guide management of patients with non-transfusion-depedent-thalassemia treated with deferasirox: THALASSA study extension analysis (Abstract). Haematologica 2013;98:486.